Smaller meals, weight and health / 01
Did semaglutide help beyond making meals feel filling?
A smaller meal may leave you satisfied for longer. Researchers checked weight, major health problems and unwanted effects, helping you consider the gains alongside the harms.
What is the short answer about weight and health?
Feeling full for longer may make eating less seem easier. With semaglutide, patients lost weight and some groups had fewer major problems affecting kidneys or hearts [2][3][4]. GLP-1 is a hormone from your gut, a chemical that helps control fullness and sugar; semaglutide has similar effects. These results don't settle your own benefit.
The medicine remains active after the gut hormone has broken down and delays stomach emptying. Nausea and other digestive trouble can make treatment difficult [5][7]. Gallstones are another concern; these hard lumps form in the gallbladder, where you store digestive fluid. A trial also found more eye damage in some people with diabetes.
I'd ask about discomfort alongside the hoped-for loss of weight. The patients' other illnesses and medicines matter when judging their results. Your own health may change how much help or discomfort you get. A large study still can't promise how you'll feel.
Why does the actual medicine in a study matter?
Ozempic and Wegovy both contain semaglutide and require a prescription. Your gut releases GLP-1 around mealtimes, helping keep blood sugar controlled and your stomach satisfied. Semaglutide acts like that hormone, so the medicine produces similar effects. The medicine doesn't break down as quickly, which keeps the effects going longer.
In blood, semaglutide attaches to a protein that helps prolong the medicine's activity. Your own GLP-1 breaks down sooner than the medicine does. That difference helps explain why the medicine's effects last longer.
The tested medicines had checks on their contents and preparation. An unchecked product may not match the medicine given to patients. You can't settle that question from a familiar name on your bottle.
How can the medicine lower sugar and leave you fuller?
Semaglutide increases insulin release from the pancreas when your sugar is running high. Your pancreas, the gland supplying insulin, sits behind your stomach. Semaglutide acts like GLP-1 and also lowers the body's release of the hormone used to raise blood sugar. As sugar falls, the extra release of insulin weakens.
Your stomach keeps food longer before passing the meal onward, prolonging fullness. That slowing can also leave you nauseated or uncomfortable. Your brain helps control hunger, too, so stomach changes aren't the whole explanation.
Mice and rats given semaglutide ate less and chose food differently [6]. The medicine reached several brain areas that help control appetite. Their bodies didn't burn less energy despite the animals eating less. Your own energy and weight loss can't be predicted from that animal experiment.
What happened to weight, heart trouble and kidney disease?
Adults without diabetes lost weight during the study called STEP 1. Through week 68, average weight change was −14.9% with semaglutide and −2.4% with placebo [4]. The placebo had the medicine's appearance, with the active ingredient left out. Your weight loss won't necessarily match the average.
A separate trial compared weight loss directly, and tirzepatide patients lost more on average. The study included 751 adults with obesity, enough extra fat to threaten health. Average changes at week 72 were −20.2% with tirzepatide and −13.7% with semaglutide [1]. You'll still need to consider how either medicine fits your health.
Fewer serious heart problems were counted with semaglutide in SELECT [3]. The 17,604 patients had extra weight, together with disease involving hearts or blood vessels. The count combined deaths linked to heart problems, heart attacks and strokes; none of these patients had diabetes. Another study, SUSTAIN-6, found a lower combined count in high-risk diabetes patients [7].
Semaglutide lowered the FLOW trial's combined total of serious kidney trouble and deaths [2]. Lasting kidney disease and type 2 diabetes affected the 3,533 patients. Researchers counted badly worsened kidney function, kidney failure and deaths linked to kidneys or heart problems. When researchers add kidney trouble and deaths into one count, a lower total doesn't establish that each kind of illness or each cause of death became less common on its own.
What stomach, gallbladder and eye problems were found?
People trying semaglutide themselves offer reports from research use, without a controlled trial checking what caused their experiences. Some describe smaller portions, fewer cravings and weight loss. Other accounts describe constipation, nausea, diarrhea, vomiting or stomach acid coming back into the throat. Burping and early tiredness appear too; the reports don't give reliable chances of these problems for you.
A review found digestive trouble was the main difficulty with tolerating semaglutide [5]. Problems involving the gallbladder and gallstones also became more likely. You digest fat with help from fluid stored in your gallbladder. A gallstone can block the fluid's passage and cause pain.
That review didn't settle whether semaglutide causes pancreas damage or thyroid cancer [5]. Your pancreas supplies insulin and helps with digestion. Your thyroid helps set your body's pace from its place in your neck. Those concerns weren't established as harm caused in people by the medicine.
More diabetes-related eye damage occurred with semaglutide during SUSTAIN-6 [7]. The concern involved patients with existing eye disease and fast blood-sugar improvement. A quick sugar drop may briefly make existing eye trouble worse. The trial didn't establish that the speed of the drop caused the damage.
How far can the large human studies guide your choice?
Researchers compared semaglutide with placebo or another treatment in large groups of people. They checked weight and serious illness, going beyond a changed blood test. You can ask whether those patients had health problems like yours.
More patients and longer checks give researchers more chances to find unwanted effects. Your health and the medicine's contents can affect what happens to you. Whether treatment continues matters, too; benefits aren't assured after stopping. Animal BPC-157 research and a blood NAD+ rise can't offer equally strong proof.
Some peptide medicines have helped people with particular health problems. Other proposed treatments have barely been tested in people. You can't expect matching benefits just because both treatments are called peptides.